Abstract
Diabetes mellitus is currently considered to be an epidemic disease. Approximately a third of individuals with type 1 and type 2 diabetes develop persistent albuminuria, lose renal function, and are at increased risk of cardiovascular and other microvascular complications. Diabetic nephropathy (DN) is the primary cause of end stage renal disease throughout the world. Microvascular dysfunction in the glomerulus appears as an early pathogenic event in progression of this renal complication. In recent years, studies with animal knockout (KO) models have revealed that uncoupling of the vascular endothelial growth factor/nitric oxide (VEGF/NO) axis leads to the glomerular alterations that characterize diabetic nephropathy. Therefore, new therapeutic alternatives may usefully target VEGF overproduction or endothelial nitric oxide availability. Recent studies also demonstrate a role for adenosine receptors in glomerular physiology and VEGF production that looks promising for therapeutic intervention of the evolution of diabetic nephropathy. However further progress is required in order to understand the dynamics of local adenosine production, in particular the extracellular metabolism of adenine nucleotides by ectoenzymes and the role of nucleoside transporters on external adenosine accumulation in the glomerulus in the pathological state. So far there is no assay that is sufficiently sensitive and accurate for subclinical diagnoses of this renal disease, which is complicated and costly to patients with often devastating effects. Current studies using proteomics offer promising alternatives for the identification of new renal injury markers. It is hoped these will permit evaluation of new therapeutic tools for more opportune intervention of this disease.
Keywords: Diabetic nephropathy, adenosine receptors, VEGF, glomerulus
Current Vascular Pharmacology
Title: Do Adenosine Receptors Offer New Therapeutic Options for Diabetic Nephropathy?
Volume: 7 Issue: 4
Author(s): Rody San Martin, Denisse Valladares, Horacio Roa, Evelin Troncoso and Luis Sobrevia
Affiliation:
Keywords: Diabetic nephropathy, adenosine receptors, VEGF, glomerulus
Abstract: Diabetes mellitus is currently considered to be an epidemic disease. Approximately a third of individuals with type 1 and type 2 diabetes develop persistent albuminuria, lose renal function, and are at increased risk of cardiovascular and other microvascular complications. Diabetic nephropathy (DN) is the primary cause of end stage renal disease throughout the world. Microvascular dysfunction in the glomerulus appears as an early pathogenic event in progression of this renal complication. In recent years, studies with animal knockout (KO) models have revealed that uncoupling of the vascular endothelial growth factor/nitric oxide (VEGF/NO) axis leads to the glomerular alterations that characterize diabetic nephropathy. Therefore, new therapeutic alternatives may usefully target VEGF overproduction or endothelial nitric oxide availability. Recent studies also demonstrate a role for adenosine receptors in glomerular physiology and VEGF production that looks promising for therapeutic intervention of the evolution of diabetic nephropathy. However further progress is required in order to understand the dynamics of local adenosine production, in particular the extracellular metabolism of adenine nucleotides by ectoenzymes and the role of nucleoside transporters on external adenosine accumulation in the glomerulus in the pathological state. So far there is no assay that is sufficiently sensitive and accurate for subclinical diagnoses of this renal disease, which is complicated and costly to patients with often devastating effects. Current studies using proteomics offer promising alternatives for the identification of new renal injury markers. It is hoped these will permit evaluation of new therapeutic tools for more opportune intervention of this disease.
Export Options
About this article
Cite this article as:
Martin San Rody, Valladares Denisse, Roa Horacio, Troncoso Evelin and Sobrevia Luis, Do Adenosine Receptors Offer New Therapeutic Options for Diabetic Nephropathy?, Current Vascular Pharmacology 2009; 7 (4) . https://dx.doi.org/10.2174/157016109789043964
DOI https://dx.doi.org/10.2174/157016109789043964 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cannabidiol as a Putative Novel Therapy for Diabetic Retinopathy: A Postulated Mechanism of Action as an Entry Point for Biomarker-Guided Clinical Development
Current Pharmacogenomics and Personalized Medicine The Genetics of Small-Vessel Disease
Current Medicinal Chemistry Gold Nanoparticles - Synthesis and Applications in Cancer Management
Recent Patents on Materials Science Ectodomain Shedding of ACE and ACE2 as Regulators of Their Protein Functions
Current Enzyme Inhibition Neurodegenerative Diseases and Flavonoids: Special Reference to Kaempferol
CNS & Neurological Disorders - Drug Targets Hypertension in Hemodialysis Patients
Current Hypertension Reviews Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
Current HIV Research Advances on Semisynthesis, Total Synthesis, and Structure-Activity Relationships of Honokiol and Magnolol Derivatives
Mini-Reviews in Medicinal Chemistry Selected Problems on Ion Chromatography Determinations of Trace Elements in Clinical Samples
Current Chromatography Synthesis, Docking and Antidiabetic Activity of Some Newer Benzamide Derivatives as Potential Glucokinase Activators
Letters in Drug Design & Discovery Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease
Cardiovascular & Hematological Disorders-Drug Targets In Vitro and In Vivo Experimental Model-based Approaches for Investigating Anti-inflammatory Properties of Coumarins
Current Medicinal Chemistry Role of CYP2E1 in Mitochondrial Dysfunction and Hepatic Injury by Alcohol and Non-Alcoholic Substances
Current Molecular Pharmacology Adherence to Treatment, Arterial Stiffness and Cognitive Function in Irbesartan- Treated Newly Diagnosed Hypertensive Patients
Current Vascular Pharmacology ACE and ACE2 in Inflammation: A Tale of Two Enzymes
Inflammation & Allergy - Drug Targets (Discontinued) Cutaneous Adverse Drug Reactions Caused by Antituberculosis Drugs
Inflammation & Allergy - Drug Targets (Discontinued) Herbal Medicines for Diabetes Management and its Secondary Complications
Current Diabetes Reviews Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets Ferritin and Percent Transferrin Saturation Levels Predict Type 2 Diabetes Risk and Cardiovascular Disease Outcomes
Current Diabetes Reviews Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome
Current Pharmaceutical Design